JW 0106 + C 2101
Alternative Names: JW-0106 + C-2101Latest Information Update: 31 Mar 2025
At a glance
- Originator JW Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 12 Nov 2024 JW Pharmaceutical completes a phase I trial in Unspecified (In volunteers) in South Korea (PO) (NCT06816719)
- 02 Sep 2024 Phase-I clinical trials in Unspecified (In volunteers) in South Korea (PO)